The latest news and information from Oncotarget

Researchers and scientists studying treatments for Triple Negative Breast Cancer have discovered that the hormone-resistant cancer cells are more likely to accept treatment if they release a certain protein named Estrogen Receptor Beta. Specifically, the proteins which tells the cancer cells where to spread and divide, cyclin-dependent kinases, were affected. The Estrogen Receptor Beta can be found in patients without Estrogen Receptor Alpha, allowing researchers to narrow the target receptor down and further explore the effects. Because this form of cancer is particularly aggressive and spreads rapidly, researchers were very excited to discover this information. Follow Oncotarget on Twitter.

This discovery was tested in the lab on a mouse with the TNB breast cancer cells attached to it. The estrogen used helped slow or even prevent further growth, as well as potentially cause the tumor to regress. The head of the research department, Dr. Hawse, is looking forward to further evaluations in the lab as well as in animals. If they are able to move on to clinical trials, they believe this discovery might lead to improved effectiveness when treating Triple Negative Breast Cancer.

Watch: https://www.youtube.com/channel/UC9KZZbhJRXBvBdwE97az3GQ

The oncology publication Oncotarget provided four researchers with sponsorships to the Frontiers in Cancer Science 2017 conference. The conference was held in Singapore on November 6-8 and featured some of the world’s top scientists involved in studying potential treatments for cancer. The editor-in-chief of Oncotarget, Mikhail Blagosklonny, sponsored the researchers in order to present research on important topics in the field of oncology.

The researchers included Mohd Anas Shamsi from India, Rajni Kumari from India, Ruhi Sandeep Deshmukh from India, and Vladan Milosevic from Italy. Dr. Shamsi presented the latest information on treatments for renal cancer, while Dr. Kumari presented information on mutations of the enzyme Caspase-10. Dr. Deshmukh presented information on the regulator Cyclin F, and Dr. Milosevic discussed the resistance of tumors related to exposure to asbestos.

There were seven research institutes hosting the conference. Research institutes from Singapore included the Cancer Science Institute, the Institute of Molecular and Cell Biology, and the Genome Institute. Other institutions included Duke-NUS Medical School from the United States and Singapore, as well as the Lee Kong Chian School of Medicine. Learn more at researchgate.net

Leave a Reply

Your email address will not be published. Required fields are marked *